How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation

Blood

Volumn 127, Issue 22, 2016, Pages 2682-2692

  Waghmare, Alpana ^a,c   Englund, Janet A ^a,b   Boeckh, Michael ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUDARABINE; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TREOSULFAN;

ABNORMAL RESPIRATORY SOUND; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CASE REPORT; CELL TRANSPLANTATION; CHEMOTHERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORD BLOOD STEM CELL TRANSPLANTATION; COUGHING; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; EMERGENCY WARD; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEMATOPOIETIC CELL; HUMAN; HUMAN RHINOVIRUS; INFECTION RISK; INTENSIVE CARE UNIT; LUNG EDEMA; LYMPHOCYTE COUNT; MALE; MULTIPLE ORGAN FAILURE; MULTIPLEX POLYMERASE CHAIN REACTION; NEUTROPHIL COUNT; NOSE OBSTRUCTION; NOSE SMEAR; OXYGEN CONSUMPTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS; SCHOOL CHILD; T CELL LEUKEMIA; THORAX RADIOGRAPHY; VIRAL RESPIRATORY TRACT INFECTION; ALLOGRAFT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PNEUMONIA, VIRAL; RESPIROVIRUS; RESPIROVIRUS INFECTIONS; RISK FACTOR;

ALLOGRAFTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PNEUMONIA, VIRAL; RESPIROVIRUS; RESPIROVIRUS INFECTIONS; RIBAVIRIN; RISK FACTORS;

EID: 84974556074     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-634873     Document Type: Article

References (162)

1. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208-214.
2. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193(12):1619-1625.
3. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195-1204.
4. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872-1880.
5. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014;123(21):3263-3268.
6. Kmeid J, Vanichanan J, Shah DP, et al. Outcomes of influenza infections in hematopoietic cell transplant recipients: application of an immunodeficiency scoring index. Biol Blood Marrow Transplant. 2016;22(3):542-548.
7. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46(3):402-412.
8. Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett. 2016;370(2):358-364.
9. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143(4):455-467.
10. Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144(5):344-349.
11. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013;57(12):1731-1741.
12. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19(4):589-596.
13. Seo S, Xie H, Campbell AP, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis. 2014;58(10):1357-1368.
14. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011;117(19):5050-5056.
15. Choi SM, Xie H, Campbell AP, et al. Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. J Infect Dis. 2012;206(12):1872-1877.
16. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220-1226.
17. de Lima CR, Mirandolli TB, Carneiro LC, et al. Prolonged respiratory viral shedding in transplant patients. Transplant Infect Dis. 2014;16(1):165-169.
18. van der Vries E, Stittelaar KJ, van Amerongen G, et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 2013;9(5):e1003343.
19. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44(8):453-455.
20. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56(2):258-266.
21. Milano F, Campbell AP, Guthrie KA, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115(10):2088-2094.
22. Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61(2):192-202.
23. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28(2):222-242.
24. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(suppl 5):S344-S351.
25. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755-2763.
26. Torres HA, Aguilera EA, Mattiuzzi GN, et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007;92(9):1216-1223.
27. Boeckh M, Englund J, Li Y, et al; NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245-249.
28. Molinos-Quintana A, Pérez-de Soto C, Gómez-Rosa M, Pérez-Simón JA, Pérez-Hurtado JM. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant. 2013;48(2):265-268.
29. Gueller S, Duenzinger U, Wolf T, et al. Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transplant Infect Dis. 2013;15(4):435-440.
30. Marcelin JR, Wilson JW, Razonable RR, Mayo Clinic HO. Transplant Infectious Diseases S. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transplant Infect Dis. 2014;16(2):242-250.
31. Gross AE, Bryson ML. Oral Ribavirin for the Treatment of Noninfluenza Respiratory Viral Infections: A Systematic Review. Ann Pharmacother. 2015;49(10):1125-1135.
32. MD Anderson Cancer Center. An open label randomized controlled trial to prevent the progression of respiratory syncytial virus upper respiratory tract infection to lower respiratory tract infection in patients after hematopoietic stem cell transplant. Available at: https://clinicaltrials.gov/ct2/show/NCT01502072. Accessed January 6, 2016.
33. Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995;21(2):376-379.
34. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 1997;102(3A):10-18.
35. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479-484.
36. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94(8):1101-1108.
37. Truven Health Analytics. Redbook online. http://sites.truvenhealth.com/redbook/index.html. Accessed September 1, 2015.
38. Chemaly RF, Ghantoji SS, Shah DP, et al. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol. 2014;36(6):e376-e381.
39. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transplant Infect Dis 2013;15(3):219-232.
40. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39(9):1300-1306.
41. Shah DP, El Taoum KK, Shah JN, et al. Characteristics and outcomes of pandemic 2009/H1N1 versus seasonal influenza in children with cancer. Pediatr Infect Dis J. 2012;31(4):373-378.
42. Karapinar DY, Ay Y, Karzaoǧlu Z, et al. Experience of pandemic influenza with H1N1 in children with leukemia. Pediatr Hematol Oncol. 2011;28(1):31-36.
43. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44(7):964-967.
44. Maeda M, Fukunaga Y, Asano T, Migita M, Ueda T, Hayakawa J. Zanamivir is an effective treatment for influenza in children undergoing therapy for acute lymphoblastic leukemia. Scand J Infect Dis. 2002;34(8):632-633.
45. Boudreault AA, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood and Marrow Transplant. 2011;17(7):979-986.
46. Boivin G. Detection and management of antiviral resistance for influenza viruses. Influenza Other Respi Viruses. 2013;7(suppl 3):18-23.
47. Chen LF, Dailey NJ, Rao AK, et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis. 2011;203(6):838-846.
48. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010;50(9):1252-1255.
49. Hernandez JE, Adiga R, Armstrong R, et al; eIND Peramivir Investigators. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis. 2011;52(6):695-706.
50. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther. 2013;18(5):651-661.
51. Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infection Chemother. 2008;14(4):308-310.
52. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood. 2010;115(7):1331-1342.
53. Tamura D, DeBiasi RL, Okomo-Adhiambo M, et al. Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J Infect Dis. 2015;212(8):1209-1213.
54. Eshaghi A, Shalhoub S, Rosenfeld P, et al. Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient. Antimicrob Agents Chemother. 2014;58(12):7188-7197.
55. Seo S, Englund JA, Nguyen JT, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther. 2013;18(3):377-386.
56. Kim WY, Young Suh G, Huh JW, et al; Korean Society of Critical Care Medicine H1N1 Collaborative. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother. 2011;55(12):5703-5709.
57. Hoopes JD, Driebe EM, Kelley E, et al. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One. 2011;6(12):e29778.
58. National Institute of Allergy and Infectious Diseases (NIAID). A randomized double-blind phase 2 study comparing the efficacy, safety, and tolerability of combination antivirals (amantadine, ribavirin, oseltamivir versus oseltamivir for the treatment of influenza in adults at risk for complications. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01227967. Accessed November 24, 2015.
59. Duval X, van der Werf S, Blanchon T, et al; Bivir Study Group. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7(11):e1000362.
60. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98(3):573-578.
61. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012;119(12):2738-2745, quiz 2969.
62. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60(1):51-59.
63. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50(2):774-777.
64. Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol. 2009;145(5):667-669.
65. Kamble RT, Bollard C, Demmler G, LaSala PR, Carrum G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant. 2007;40(7):699-700.
66. Shachor-Meyouhas Y, Ben-Barak A, Kassis I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. Pediatr Blood Cancer. 2011;57(2):350-351.
67. Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. The human metapneumovirus: a case series and review of the literature. Transplant Infect Dis. 2011;13(3):324-328.
68. Kitanovski L, Kopriva S, Pokorn M, et al. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol. 2013;35(7):e311-e313.
69. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis. 2004;39(5):673-680.
70. Ljungman P, Gleaves CA, Meyers JD. Respiratory virus infection in immunocompromised patients. Bone Marrow Transplant. 1989;4(1):35-40.
71. Bredius RG, Templeton KE, Scheltinga SA, Claas EC, Kroes AC, Vossen JM. Prospective study of respiratory viral infections in pediatric hemopoietic stem cell transplantation patients. Pediatr Infect Dis J. 2004;23(6):518-522.
72. Templeton KE, Bredius RG, Scheltinga SA, Claas EC, Vossen JM, Kroes AC. Parainfluenza virus 3 infection pre- and post-haematopoietic stem cell transplantation: re-infection or persistence? J Clin Virol 2004;29(4):320-322.
73. Abandeh FI, Lustberg M, Devine S, Elder P, Andritsos L, Martin SI. Outcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study. Bone Marrow Transplant. 2013;48(12):1554-1557.
74. Seo S, Xie H, Karron RA, et al. Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes. Bone Marrow Transplant. 2014;49(9):1205-1211.
75. Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant. 2001;7 suppl:19S-22S.
76. Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med. Mar 17 1997;102(3A):48-52.
77. Gerna G, Piralla A, Rovida F, et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol. 2009;81(8):1498-1507.
78. Kaiser L, Aubert JD, Pache JC, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174(12):1392-1399.
79. Schuurmans MM, Isenring BD, Jungo C, et al. Clinical features and outcomes of influenza infections in lung transplant recipients: a single-season cohort study. Transplant Infect Dis. 2014;16(3):430-439.
80. Rubin LG, Levin MJ, Ljungman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-e100.
81. Shahgholi E, Ehsani MA, Salamati P, Maysamie A, Sotoudeh K, Mokhtariazad T. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer. 2010;54(5):716-720.
82. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2013;8:CD006484.
83. Vinograd I, Eliakim-Raz N, Farbman L, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer. 2013;119(22):4028-4035.
84. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2013;10:CD008983.
85. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-645.
86. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008;42(10):637-641.
87. Storek J, Viganego F, Dawson MA, et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood. 2003;101(8):3319-3324.
88. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol. 2003;31(10):941-952.
89. Ambati A, Boas LS, Ljungman P, et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant. 2015;50(6):858-864.
90. Grohskopf LASL, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015;64(30):818-825.
91. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med. 1997;102(3A):55-60.
92. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11(1):1-5.
93. Renaud C, Boudreault AA, Kuypers J, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis. 2011;17(4):653-660, quiz 765.
94. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med. 2009;361(23):2296-2297.
95. American Academy of Pediatrics. Respiratory syncytial virus. In:Kimberlin DW, Brady MY, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee for Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:667-676.
96. Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant. 2010;16(9):1265-1271.
97. Shachor-Meyouhas Y, Zaidman I, Kra-Oz Z, Arad-Cohen N, Kassis I. Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department. J Pediatr Hematol Oncol. 2013;35(2):124-128.
98. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711-722.
99. Mackman RL, Sangi M, Sperandio D, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015;58(4):1630-1643.
100. Samuel D, Xing W, Niedziela-Majka A, et al. GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrob Agents Chemother. 2015;59(11):7109-7112.
101. Gilead Sciences. Efficacy, pharmacokinetics, and safety of gs-5806 in hospitalized adults with respiratory syncytial virus (RSV) infection. Available at: https://clinicaltrials.gov/ct2/show/NCT02135614. Accessed November 24, 2015.
102. Gilead Sciences. GS-5806 in lung transplant (LT) recipients with respiratory syncytial virus (RSV) infection. Available at: https://clinicaltrials.gov/ct2/show/NCT02534350. Accessed November 24, 2015.
103. Gilead Sciences. GS-5806 in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the upper respiratory tract. Available at: https://clinicaltrials.gov/ct2/show/NCT02254408. Accessed November 24, 2015.
104. Gilead Sciences. GS-5806 in hematopoietic cell transplant recipients with respiratory syncytial virus (RSV) infection of the lower respiratory tract. Available at: https://clinicaltrials.gov/ct2/show/NCT02254421. Accessed November 24, 2015.
105. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048-2058.
106. Alios Biopharma Inc. A study of ALS-008176 in infants hospitalized with RSV. Available at: https://clinicaltrials.gov/ct2/show/NCT02202356. Accessed November 24, 2015.
107. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107(19):8800-8805.
108. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011;183(4):531-538.
109. Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. Journal Heart Lung Transplant. 2016;35(2):213-221.
110. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348(9):867-868.
111. Chan-Tack KM, Kim C, Moruf A, Birnkrant DB. Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014). Antivir Ther. 2015;20(5):561-564.
112. Marty FM, Man CY, van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis. 2014;209(4):542-550.
113. GlaxoKlineSmith. A study of intravenous zanamivir versus oral oseltamivir in adults and adolescents hospitalized with influenza (ZORO). Available at: https://clinicaltrials.gov/ct2/show/NCT01231620. Accessed November 24, 2015.
114. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, Group MS; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167-1175.
115. MDVI LLC. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02008344. Accessed November 24, 2015.
116. Haffizulla J, Hartman A, Hoppers M, et al; US Nitazoxanide Influenza Clinical Study Group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014;14(7):609-618.
117. Romark Laboratories. A phase III Randomized double-blind placebo controlled trial to evaluate the efficacy and safety of nitazoxanide in the treatment of acute uncomplicated influenza. Available at: https://clinicaltrials.gov/ct2/show/NCT02612922. Accessed November 24, 2015.
118. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006;50(4):1470-1479.
119. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007;196(10):1493-1499.
120. Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009;4(11):e7838.
121. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One. 2009;4(11):e7788.
122. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012;206(12):1844-1851.
123. Waghmare A, Wagner T, Andrews R, et al. Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children. J Pediatric Infect Dis Soc. 2015;4(2):114-118.
124. Chalkias S, Mackenzie MR, Gay C, et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transplant Infect Dis. 2014;16(1):141-144.
125. Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transplant Infect Dis. 2013;15(1):E28-E32.
126. Guzman-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transplant Infect Dis. 2012;14(4):427-433.
127. Ansun Biopharma, Inc. A phase II, randomized, double-blind, placebo-controlled study to examine the effects of DAS181 in immunocompromised subjects with lower respiratory tract parainfluenza infection on supplemental oxygen (DAS181-2-05). Available at: https://clinicaltrials.gov/ct2/show/NCT01644877. Accessed December 7, 2015.
128. Hayden FG, Herrington DT, Coats TL, et al; Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36(12):1523-1532.
129. Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis. 2002;2(5):264.
130. Lambert JN. BTA798 is an orally bioavailable and potent inhibitor of human rhinovirus both in vitro and in an experimental human infection model. In: 51th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
131. Matz J. Vapendavir significantly improves upper respiratory symptoms of naturally acquired rhinovirus infection in asthmatic adults: results of a phase 2 clinical trial. Eur Respir J. 2013;42(suppl 57):307s.
132. Biota Scientific Management Pty Ltd. A phase 2 study of vapendavir in asthmatic adults with symptomatic human rhinovirus infection (SPIRITUS). Available at: https://clinicaltrials.gov/ct2/show/NCT02367313. Accessed November 24, 2015.
133. Mello C, Aguayo E, Rodriguez M, et al. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob Agents Chemother. 2014;58(3):1546-1555.
134. Basta HA, Ashraf S, Sgro JY, Bochkov YA, Gern JE, Palmenberg AC. Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance. Virology. 2014;448:82-90.
135. Falsey AK, Khorana M, Walsh E, Sorrentino M, Murray R, Betts R. Use of high titer rsv immunoglobulin (RI-001-RSV IVIG) in immunocompromised adults. In: IDSA International Conference, Breaking the Rules! August 21-23, 2013; Chicago, IL.
136. Falsey AK, Khorana M, Walsh E, Sorrentino M, Murray R, Betts R. A summary of the study of a polyclonal human IVIG with standardized high levels of RSV neutralizing antibodies. In: IDSA International Conference, Breaking the Rules! August 21-24, 2013; Chicago, IL.
137. Ramilo O, Lagos R, Sáez-Llorens X, et al; Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33(7):703-709.
138. O'Brien KL, Chandran A, Weatherholtz R, et al; Respiratory Syncytial Virus (RSV) Prevention study group. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1398-1408.
139. MedImmune LLC. A phase 1b/2a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of MEDI8897, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy preterm infants (MEDI8897 1b). Available at: https://clinicaltrials.gov/ct2/show/NCT02290340. Accessed November 24, 2015.
140. Genentech, Inc. A study of MHAA4549A in combination with oseltamivir versus oseltamivir in patients with severe influenza A infection. Available at: https://clinicaltrials.gov/ct2/show/NCT02293863. Accessed November 24, 2015.
141. National Institute of Allergy and Infectious Diseases (NIAID). Study in healthy volunteers to evaluate the efficacy and safety of CR6261 in an H1N1 influenza healthy human challenge model. https://clinicaltrials.gov/ct2/show/NCT02371668. Accessed December 21, 2015.
142. MedImmune LLC. A phase 1b/2a to evaluate the safety of MEDI8852 in adults with uncomplicated influenza. Available at: https://clinicaltrials.gov/ct2/show/NCT02603952. Assessed December 22, 2015.
143. Ramos EL, Mitcham JL, Koller TD, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis. 2015;211(7):1038-1044.
144. INSIGHT FLU005 IVIG Pilot Study Group. INSIGHT FLU005: an anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. J Infect Dis. 2016;213(4):574-578.
145. National Institute of Allergy and Infectious Diseases. Evaluating the safety and efficacy of anti-influenza intravenous hyperimmune immunoglobulin (IVIG) in adults hospitalized with influenza. Available at: https://clinicaltrials.gov/ct2/show/NCT02287467. Assessed December 22, 2015.
146. National Institute of Allergy and Infectious Diseases (NIAID). Comparing the efficacy and safety of high-titer versus low-titer anti-influenza immune plasma for the treatment of severe influenza A. Available at: https://clinicaltrials.gov/ct2/show/NCT02572817. Assessed December 23, 2015.
147. University of Virginia. Treatment with omalizumab to improve the asthmatic response to rhinovirus experimental infection with rhinovirus. Available at: https://clinicaltrials.gov/ct2/show/NCT02388997. Assessed December 21, 2015.
148. GlaxoSmithKline. Safety, reactogenicity and immunogenicity study of different formulations of GlaxoSmithKline (GSK) biologicals' investigational RSV vaccine (GSK3003891A), in healthy women. Available at: https://clinicaltrials.gov/ct2/show/NCT02360475. Assessed December 23, 2015.
149. MedImmune LLC. A study to evaluate the efficacy of MEDI7510 in older adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02508194. Assessed December 22, 2015.
150. Novavax. A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization. Available at: https://clinicaltrials.gov/ct2/show/NCT02624947. Assessed December 23, 2015.
151. Karron RA, San Mateo J, Thumar B, et al. Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children. J Pediatric Infect Dis Soc. 2015;4(4):e143-e146.
152. St. Jude Children's Research Hospital. A study to assess the safety of live intranasal Sendai virus vaccine in children and toddlers. Available at: https://clinicaltrials.gov/ct2/show/NCT00186927. Assessed December 23, 2015.
153. Mackow N, Amaro-Carambot E, Liang B, et al. Attenuated human parainfluenza virus type 1 (HPIV1) expressing the fusion glycoprotein of human respiratory syncytial virus (RSV) as a bivalent HPIV1/RSV vaccine. J Virol. 2015;89(20):10319-10332.
154. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012;31(2):109-114.
155. National Institute of Allergy and Infectious Diseases (NIAID). Evaluation of the safety and immunogenicity of a live attenuated human metapneumovirus vaccine. Available at: https://clinicaltrials.gov/ct2/show/NCT01255410. Assessed December 23, 2015.
156. Aoki T, Koh K, Kawano Y, et al. Safety of live attenuated high-titer varicella-zoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients [published online ahead of print December 31, 2015]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2015.12.025.
157. Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014; 20(2):285-287.
158. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290-299.
159. Nakamura R, Rosa CL, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3(2):e87-e98.
160. Einsele H, Löffler J, Kapp M, Rasche L, Mielke S, Grigoleit UG. Immunotherapy for viral and fungal infections. Bone Marrow Transplant. 2015;50(suppl 2):S51-S54.
161. Arasaratnam RJ, Leen AM. Adoptive T cell therapy for the treatment of viral infections. Ann Transl Med. 2015;3(18):278.
162. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.